BioWorld

Sep. 21, 2004

View Archived Issues

Tarceva Phase III: 'Modest' Benefit In Pancreas Cancer

Already strong in lung cancer, Tarceva proved its mettle in a Phase III study combined with gemcitabine as a first-line therapy against pancreatic cancer, meeting the primary endpoint of survival improvement. (BioWorld Today) Read More

Medarex Partners With Pfizer In Potential $510M Antibody Deal

Read More

Phase III Miss For Ceplene Halves Maxim's Stock Price

Read More

Acambis Falls On Cancelled Smallpox Contract From CDC

Read More

Other News To Note

Read More